Ozempic vs Wegovy: Same Molecule, Two Very Different Prescriptions

Yes — chemically, they are identical. Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. A GLP-1 receptor agonist is a medication that mimics a natural gut hormone released after you eat, which slows stomach emptying, signals fullness to your brain, and helps the pancreas release insulin when blood sugar rises.

If you put the two side by side in a lab, you would not be able to tell the molecules apart. What differs is everything wrapped around that molecule: the dose ceiling, the FDA-approved indication printed on the label, the shape of the injector pen, the box it comes in, and — for most people, the part that actually matters — how insurance treats it.

This is not unusual in pharmacology. The same compound is routinely sold under different brand names for different conditions, because the FDA approves a drug-indication pair, not just a drug. Bupropion is sold as an antidepressant and as a smoking-cessation aid. Finasteride is sold at one dose for prostate enlargement and a lower dose for hair loss. Tirzepatide follows the same pattern, sold as Mounjaro for diabetes and Zepbound for weight management — a comparison we break down in [Mounjaro vs Zepbound: same drug, different label](/blog/mounjaro-vs-zepbound-same-drug-different-label).

So when someone tells you "Wegovy is the weight loss one and Ozempic is the diabetes one," they are right about the labels and wrong about the chemistry. Understanding that distinction is what lets you have a productive conversation with your prescriber about which version fits your situation.

Ozempic is dosed up to 2.0 mg once weekly, while Wegovy is dosed up to 2.4 mg once weekly — and in 2026 the FDA cleared a higher 7.2 mg Wegovy dose for people who plateau on 2.4 mg.

Both start in the same place. Everyone begins at 0.25 mg weekly for four weeks, not because that dose does much, but because it lets your digestive system adapt. From there:

• •Ozempic: 0.25 → 0.5 → 1.0 → 2.0 mg
• •Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg

Notice that Wegovy has an extra rung on the ladder — 1.7 mg — before the top dose. That intermediate step exists specifically because the higher doses are harder on the stomach, and a gentler climb improves the odds you stay on the medication long enough to benefit.

On paper, 0.4 mg separates the two ceilings. That sounds trivial. In practice, the dose-response curve for semaglutide keeps climbing through 2.4 mg, which is why the weight-management trials used that dose and not 2.0 mg. More drug at the receptor means stronger appetite suppression and stronger delay in stomach emptying — and, predictably, more nausea, more constipation, and more of the side effects covered in [why GLP-1 nausea happens and how to ease it](/blog/glp1-nausea-why-it-happens-and-how-to-ease-it).

The pens differ too. Ozempic comes as a multi-dose pen you dial and reuse across several weeks. Wegovy comes as single-dose pens — one pen, one injection, done. Neither is better; some people prefer not having to dial a dose, others prefer fewer pens in the fridge.

The clearest number comes from STEP 1 (New England Journal of Medicine, 2021), which randomized 1,961 adults with overweight or obesity — and without diabetes — to semaglutide 2.4 mg or placebo. After 68 weeks, the semaglutide group lost an average of 14.9% of body weight, compared with 2.4% on placebo. For a 200-pound person, that is roughly 30 pounds.

The diabetes doses produce less. Across the SUSTAIN trial program, semaglutide 1.0 mg weekly typically produced around 4 to 6 kg (roughly 9 to 13 pounds) of weight loss, and the 2.0 mg dose studied in SUSTAIN FORTE landed near 7 kg. Part of that gap is the dose, and part is that people with type 2 diabetes consistently lose less weight on GLP-1 medications than people without it — a real and somewhat frustrating pattern seen across every drug in the class.

A word of caution about averages: STEP 1's 14.9% is a mean, and the spread around it is wide. About a third of participants lost more than 20% of their body weight. A meaningful minority lost under 5%. Where you land depends on your starting weight, your dose tolerance, whether you hold protein and strength training steady, and factors nobody has fully mapped yet.

It is also worth knowing what semaglutide is not the strongest option for. In SURMOUNT-5, the head-to-head trial published in 2025, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. We unpack that trial in [tirzepatide vs semaglutide: the SURMOUNT-5 head-to-head](/blog/tirzepatide-vs-semaglutide-surmount-5-head-to-head).

Because they were studied in different populations, and the FDA only approves what was actually tested.

Wegovy's cardiovascular approval came from the SELECT trial (NEJM, 2023), which enrolled more than 17,600 adults who had established cardiovascular disease and overweight or obesity — but *not* diabetes. Over an average of about 40 months, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by roughly 20% compared with placebo. That result earned Wegovy an FDA indication in 2024 to reduce cardiovascular risk in that specific group.

Ozempic carries its own outcome approvals, but for people with type 2 diabetes. The SUSTAIN-6 trial supported a cardiovascular indication in diabetes, and the FLOW trial (NEJM, 2024) showed semaglutide 1.0 mg reduced the risk of major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease — which led to a kidney indication.

So the same molecule is proven to protect hearts in people without diabetes (as Wegovy) and to protect kidneys in people with diabetes (as Ozempic). This is not marketing sleight of hand; it reflects two genuinely different evidence bases.

Why it matters to you: these indications drive insurance coverage. An insurer that refuses to cover "weight loss medication" may cover Wegovy for a member with documented cardiovascular disease, because the prescription is then for cardiovascular risk reduction. If you have a cardiac history, that framing is worth raising with your prescriber — and our [guide to appealing a GLP-1 insurance denial](/blog/glp1-insurance-denial-how-to-appeal-prior-authorization-2026) walks through how to document it.

If you have type 2 diabetes, Ozempic is usually far easier. If you don't, the honest answer is that both can be difficult, and Wegovy is the one designed for your situation.

Most commercial insurance plans treat diabetes medications as core covered benefits. Weight-management medications are frequently carved out entirely — the plan simply excludes the category, and no amount of prior authorization paperwork changes an exclusion. That is the first thing to check: call the number on your card and ask specifically whether your plan has an *anti-obesity medication exclusion*, not just whether Wegovy is on formulary.

When coverage does exist for Wegovy, plans typically require a BMI of 30 or higher, or 27 or higher with a weight-related condition like hypertension, sleep apnea, or high cholesterol. Many also require documentation of a prior supervised weight-loss attempt.

This coverage gap is also why some people ask their doctor for Ozempic when their goal is weight loss. Be aware that prescribing a diabetes medication to someone without diabetes is off-label — legal and common, but insurance will usually refuse it without a diabetes diagnosis code, leaving you paying cash anyway.

On cash pricing: Wegovy's list price has run around $1,349 for a month's supply, but Novo Nordisk's direct-to-consumer pharmacy has offered self-pay pricing at a fraction of that, and the numbers have changed repeatedly. Check current pricing rather than trusting a figure you read months ago — we track the landscape in [GLP-1 direct-pay pricing](/blog/glp1-direct-pay-pricing-2026-lillydirect-novocare-trumprx).

The side effect profile is the same because the drug is the same — but the *intensity* tends to track the dose, so Wegovy users at 2.4 mg often report more of it.

The common effects, across both:

• •Nausea — the most reported, usually worst in the days after a dose increase and fading as your body adapts
• •Constipation — from slowed gut motility; often the most persistent complaint
• •Diarrhea, vomiting, and burping — including the notorious sulfur burps
• •Fatigue — frequently from simply eating too little, not from the drug itself
• •Injection site reactions — redness or small lumps, usually mild

The serious-but-rare risks are also identical, because they belong to semaglutide: pancreatitis, gallbladder disease (more likely with rapid weight loss), and a boxed warning about thyroid C-cell tumors seen in rodents. That warning means anyone with a personal or family history of medullary thyroid carcinoma or MEN2 should not take either medication — explained further in [GLP-1 thyroid safety](/blog/glp1-thyroid-safety-what-you-need-to-know).

One effect that is genuinely dose-linked is muscle loss. Faster weight loss means a larger share of that loss can come from lean tissue, which is why protein intake and resistance training matter more at 2.4 mg than at 0.5 mg. That concern gets sharper for women in midlife, when estrogen decline is already working against muscle — see [muscle loss on a GLP-1 in menopause](/blog/muscle-loss-on-glp1-in-menopause-sarcopenia-risk).

If side effects are the deciding factor, remember you can stay on a lower dose. A person who feels well and is losing steadily at 1.0 mg has no obligation to climb to the ceiling.

Start with your diagnosis, because that determines what is even prescribable.

If you have type 2 diabetes: Ozempic is the on-label choice, and it will almost certainly be the covered one. If weight is also a major goal and your blood sugar is controlled, it is reasonable to ask whether moving to Wegovy makes sense — but expect a coverage fight, since insurers rarely pay for the weight-management brand when the diabetes brand is available.

If you do not have diabetes but meet the BMI criteria: Wegovy is the appropriate prescription. It is the version that was studied in you, dosed for your goal, and approved for it.

If you have cardiovascular disease and overweight: Wegovy has the strongest case, because the SELECT indication is written for exactly that scenario.

Then bring three things to the appointment: your current medication list, any cardiac or kidney history, and your insurer's formulary status for both drugs (available on your plan's website, usually under "drug list"). Arriving with formulary information saves weeks — it lets your prescriber write for something that will actually be filled rather than discovering the rejection later.

And if you are in perimenopause or menopause, flag that too. Body composition, bone density, and hormone therapy all interact with GLP-1 treatment in ways worth planning for, which we cover in [talking to your doctor about GLP-1 and menopause](/blog/talking-to-your-doctor-about-glp1-and-menopause-what-to-ask).

The medication is the same. The prescription — the dose, the indication, the coverage, the plan around it — is what you are really choosing.